MedTrace Logo

Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota

NCT01182844 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-09-29

Study results available
· View outcomes & findings →

Summary

Obesity and metabolic syndrome are linked by inflammation. Gut flora seems to play an important role in the development of inflammation and metabolic syndrome in obesity. Modulation of gut flora by probiotics has been shown in animal studies to positively influence inflammation and metabolic disturbances.

Lactobacillus casei Shirota is able to decrease metabolic endotoxemia by altering gut flora composition and gut permeability which leads to an improvement in neutrophil function and insulin resistance in obesity.

The aim of the current study is to investigate the effect of Lactobacillus casei Shirota supplementation over 12 weeks on neutrophil function (phagocytosis, oxidative burst and TLR expression) in patients with metabolic syndrome.

Furthermore the investigators aim to investigate the effect of Lactobacillus casei Shirota supplementation over 12 weeks on glucose tolerance, insulin resistance, inflammation, gut flora composition, gut permeability, and endotoxemia in metabolic syndrome

Conditions

  • Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

Lactobacillus casei Shirota

3 bottles of Yakult(R) light per day

Sponsors & Collaborators

  • Vanessa Stadlbauer-Koellner, MD

    lead OTHER

Principal Investigators

  • Vanessa Stadlbauer-Köllner, MD · Dept. of Internal Medicine, Medical University of Graz, Austria

  • Harald Sourij, MD · Dept. of Internal Medicine, Medical University of Graz, Austria

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-11-30
Completion
2010-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01182844 on ClinicalTrials.gov